Ocugen

Approaching healthcare innovation with ingenuity, passion and courage to create new solutions to difficult medical challenges. Guidelines:

[Ocugen @Ocugen]

Not all age-related macular degeneration (#AMD) is the same. The two forms, Dry AMD and Wet AMD, can affect vision in different ways. #Geographicatrophy (GA), an advanced form of dry AMD, affects approximately 2–3 million people. Follow our progress as we advance #OCU410 for GA.

[Ocugen @Ocugen]

RP is a genetic condition that leads to progressive vision loss over time. #OCU400 is an investigational modifier #genetherapy designed as a potential one-time treatment for people living with RP. #RetinitisPigmentosa #Ocugen

Learn more: https://t.co/ykiBbfm4mp

[Ocugen @Ocugen]

Ocugen will participate in several investor and industry conferences this July, sharing updates on our modifier #genetherapy platform for blindness diseases. #Biotech @Piper_Sandler @OISTWEETS @asrsdocs @drsmusunuri

Read more: https://t.co/gVpdFxQ8hO

[Ocugen @Ocugen]

Understanding the retina is an important step in vision health. Many #retinaldiseases are linked to genetic mutations that can lead to vision loss. #Ocugen is advancing modifier gene therapies designed to address the causes of these rare conditions and help preserve vision.

[Ocugen @Ocugen]

#Retinitispigmentosa affects everyone differently. Early signs may include trouble seeing at night, tunnel vision, sensitivity to bright light, or other changes in vision.

If you notice changes in your vision, talk to your doctor. #Biotech #VisionHealth

[Ocugen @Ocugen]

Connie Collingsworth, Member of our Business Advisory Board and former COO of the @gatesfoundation, met with CEO @drsmusunuri this week to discuss global access partnerships as we work to advance transformative modifier gene therapies for patients around the world. #GlobalHealth

[Ocugen @Ocugen]

Ocugen will be at #BIO2026 in San Diego!

Abhi Gupta, EVP, Commercial & Business Development, will be speaking at the BIO Int'l Convention as we continue advancing our mission to enable global access for patient through effective partnerships. @IAmBiotech #Biotech #GeneTherapy

[Ocugen @Ocugen]

“I have more adaptation to light and darkness.” – Nancy

After living with #retinitispigmentosa for 31 years, Nancy shares her story and hope for the future after participating in Ocugen’s #OCU400 clinical trial. #Ocugen $OCGN

Learn more about OCU400: https://t.co/OXzETxjDpJ

[Ocugen @Ocugen]

Thank you to everyone who joined this year’s Clinical Trials at the Summit. Ocugen Chairman, CEO, and Co-Founder @drsmusunuri joined industry leaders for a panel discussion on IRDs and the importance of advancing innovative gene therapies. $OCGN #GeneTherapy #Biotech

[Ocugen @Ocugen]

Please join us in welcoming Mohamed Genead, MD, MSc as #Ocugen’s CMO.

With 20+ years of experience in ophthalmology, gene therapy, and retinal disease development, Dr. Genead brings extensive leadership and expertise as we advance transformative therapies for patients.

[Ocugen @Ocugen]

What makes #OCU400 different?

OCU400 is designed to address multiple RP mutations through a potential one-time therapy.

Follow us for updates as we advance OCU400 toward a planned BLA submission this year.

#RetinitisPigmentosa #GeneTherapy $OCGN

[Ocugen @Ocugen]

Early #OCU410ST results show:
✓ 54% reduction in atrophic lesion growth
✓ 100% of treated eyes stabilized or improved
✓ +6 letter gain in visual acuity

Hear from an OCU410ST clinical trial participant: https://t.co/znh5I8UL9R

$OCGN

[Ocugen @Ocugen]

What is #RetinitisPigmentosa (RP)?

RP is a rare inherited eye disease that can lead to vision loss over time. More than 150 genetic mutations can cause RP. #OCU400 is designed to address over 98% RP-associated gene mutations with a single dose. Share to raise awareness. $OCGN

[Ocugen @Ocugen]

Ocugen is excited to showcase our innovative modifier #genetherapy platform for inherited retinal and blindness diseases at three conferences this month. @IAmBiotech @NobleCapMkts $OCGN #InvestorRelations

🔗https://t.co/ok0itKrdvM
Noble Capital replay: https://t.co/zLQlXmzENU

[Ocugen @Ocugen]

100,000+ people with #Stargardtdisease have no FDA approved treatment. #OCU410ST aims to slow or stop disease progression, with early promising data.

Follow Ocugen and be part of something groundbreaking. #Biotech #Genetherapy $OCGN

[Ocugen @Ocugen]

Tune in on May 26, 2026, as Ocugen CEO @drsmusunuri participates in the Stifel 2026 Virtual Ophthalmology Forum. @Stifel #GeneTherapy #InvestorRelations $OCGN

Watch live: https://t.co/tgQyISN9jz

Replay available for 30 days following the event: https://t.co/uUZpRk5R5k

[Ocugen @Ocugen]

What is #Stargardtdisease?

A rare inherited retinal disease that can cause central vision loss, often beginning early in life. Ocugen’s investigational #genetherapy candidate, #OCU410ST, is designed to target disease pathways. #Biotech $OCGN

[Ocugen @Ocugen]

Momentum continues at Ocugen. With $130 million in financing secured, we are well-positioned to advance our three late-stage
programs as we work toward filing three BLAs by 2028.

Learn more: https://t.co/7nSj5EJkPZ

#GeneTherapy #Biotech #FinancialUpdate $OCGN

[Ocugen @Ocugen]

Impactful day in Ft. Lauderdale at #RetinaWorldCongress as CEO @drsmusunuri shared how Ocugen is advancing potentially one-time gene therapies for RP, Stargardt disease, and GA, while working toward three BLA filings by 2028.

@RWCRetina #GeneTherapy #Biotech $OCGN